These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 7819100)

  • 1. Primary plasma cell leukaemia.
    Dimopoulos MA; Palumbo A; Delasalle KB; Alexanian R
    Br J Haematol; 1994 Dec; 88(4):754-9. PubMed ID: 7819100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.
    García-Sanz R; Orfão A; González M; Tabernero MD; Bladé J; Moro MJ; Fernández-Calvo J; Sanz MA; Pérez-Simón JA; Rasillo A; Miguel JF
    Blood; 1999 Feb; 93(3):1032-7. PubMed ID: 9920853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-secretory multiple myeloma presenting as primary plasma cell leukaemia.
    Sureda A; Pais JR; Pascual J; Pérez Vaquero MA; Hernando JC
    Postgrad Med J; 1992 Jun; 68(800):470-2. PubMed ID: 1437933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The significance of lactate dehydrogenase and beta 2-microglobulin levels for the assessment of the prognosis and choice of therapy in multiple myeloma].
    Iakovleva SV; Andreeva NE; Izgorodin AS
    Ter Arkh; 1995; 67(7):35-9. PubMed ID: 7482303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma cell leukemia 3 months after autologous blood cell transplantation for multiple myeloma.
    Koskela K; Pelliniemi TT; Lakkala T; Remes K
    Bone Marrow Transplant; 1998 Feb; 21(3):305-7. PubMed ID: 9489657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.
    San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Delforge M; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Deraedt W; Cakana A; van de Velde H; Richardson PG
    J Clin Oncol; 2013 Feb; 31(4):448-55. PubMed ID: 23233713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Karyotype in multiple myeloma and plasma cell leukaemia.
    Weh HJ; Gutensohn K; Selbach J; Kruse R; Wacker-Backhaus G; Seeger D; Fiedler W; Fett W; Hossfeld DK
    Eur J Cancer; 1993; 29A(9):1269-73. PubMed ID: 8343266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell leukemia: from biology to treatment.
    Jelinek T; Kryukov F; Rihova L; Hajek R
    Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
    Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
    Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma.
    Dimopoulos MA; Barlogie B; Smith TL; Alexanian R
    Ann Intern Med; 1991 Dec; 115(12):931-5. PubMed ID: 1952489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
    Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
    Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
    Telek B; Méhes L; Batár P; Kiss A; Udvardy M
    Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute leukemia of plasmablastic type as terminal phase of multiple myeloma.
    Piccinini L; Artusi T; Bonacorsi G; Arigliano V
    Haematologica; 2002 Feb; 87(2):EIM04. PubMed ID: 11836178
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma cell leukaemia mimicking acute monocytic leukaemia in the course of multiple myeloma.
    Eclache V; Lusina D; Lejeune F; Casassus P; Smadja N; Lortholary P
    Nouv Rev Fr Hematol (1978); 1993 Aug; 35(4):419-22. PubMed ID: 8414961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [IgG-lambda-type multiple myeloma with plasma-cell pericardial effusion and terminal plasma-cell leukemia].
    Klug S; Höltermann F; Fritsch H
    Dtsch Med Wochenschr; 1992 Jun; 117(23):900-4. PubMed ID: 1597118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple myeloma--new therapeutic perspectives].
    Skotnicki AB; Wolska-Smoleń T; Jurczyszyn A
    Przegl Lek; 1999; 56 Suppl 1():67-72. PubMed ID: 10494186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma cell leukemia. Study of 6 patients].
    Las Heras G; Ribera JM; Abella E; Batlle M; Flores A; Millá F; Feliu E
    Sangre (Barc); 1992 Aug; 37(4):255-8. PubMed ID: 1514138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
    Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
    Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
    An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
    Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.